CDH17 Recombinant Monoclonal Antibody

Code: CSB-RA613267MA3HU

Rate （N/A）
Review （0）

Size:

50μl100μl

US$210

Quantity:

Species Reactivity: Human, Rat

Application: ELISA

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

Q12864

Target Names

CDH17

Alternative Names

BILL-cadherin antibody; CAD17_HUMAN antibody; Cadherin 16 antibody; Cadherin 16; formerly antibody; Cadherin 17 antibody; cadherin 17; LI cadherin (liver-intestine) antibody; cadherin; liver-intestine antibody; Cadherin-17 antibody; CDH16 antibody; CDH16; formerly antibody; Cdh17 antibody; FLJ26931 antibody; Formerly Cadherin 16 antibody; Formerly CDH16 antibody; HPT 1 antibody; HPT-1 cadherin antibody; human intestinal peptide-associated transporter HPT-1 antibody; human peptide transporter 1 antibody; Intestinal peptide-associated transporter HPT 1 antibody; Intestinal peptide-associated transporter HPT-1 antibody; LI-cadherin antibody; Liver Cadherin antibody; liver intestine cadherin antibody; Liver-intestine cadherin antibody

Species Reactivity

Human, Rat

Immunogen

Recombinant Human CDH17 protein

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

hIgG1

Clone No.

13C8F1

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Scope Application

ELISA Protocol

Recommended Dilution

Application	Recommended Dilution
ELISA	1:5000-1:50000

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Datasheet & COA

Antibody FAQs

Images

The Binding Activity of Macaca fascicularis CDH17 with Anti-CDH17 recombinant antibody
Activity: Measured by its binding ability in a functional ELISA. Immobilized Macaca fascicularis CDH17 (CSB-MP4664MOV) at 2 μg/mL can bind Anti-CDH17 recombinant antibody. The EC₅₀ is 2.182-2.529 ng/mL.
The Binding Activity of Rat CDH17 with Anti-CDH17 recombinant antibody
Activity: Measured by its binding ability in a functional ELISA. Immobilized Rat CDH17 (CSB-MP005042RA) at 2 μg/mL can bind Anti-CDH17 recombinant antibody. The EC₅₀ is 13.06-14.24 ng/mL.

Description

Cadherin-17, also known as liver-intestine cadherin or LI-cadherin, plays a distinctive role in cell adhesion within the gastrointestinal tract and liver. Unlike classical cadherins, CDH17 functions as a calcium-dependent adhesion molecule with seven extracellular cadherin repeats and has been implicated in intestinal epithelial organization and hepatocellular carcinoma progression. Its restricted expression pattern makes it a valuable marker for studying tissue-specific differentiation and gastrointestinal malignancies, while its involvement in signal transduction pathways continues to attract research interest.

This recombinant monoclonal antibody, clone 13C8F1, offers the reproducibility essential for longitudinal studies and multi-site collaborations. Produced using recombinant technology with a defined sequence, it eliminates the lot-to-lot variability that can compromise experimental consistency. The antibody is generated against recombinant human CDH17 protein and purified through affinity chromatography, ensuring high specificity for your target.

Functional ELISA validation demonstrates robust binding activity with impressive sensitivity. Testing against immobilized Macaca fascicularis CDH17 yielded an EC50 of 2.182–2.529 ng/mL, while rat CDH17 binding showed an EC50 of 13.06–14.24 ng/mL. This cross-species reactivity spanning human, rat, and cynomolgus macaque provides flexibility for researchers working across preclinical models and human samples. The recommended ELISA dilution range of 1:5000–1:50000 reflects the antibody's strong binding affinity, allowing economical use across multiple experiments.

Supplied in a glycerol-based PBS buffer with Proclin 300 preservative, this unconjugated antibody is well-suited for researchers investigating CDH17's role in signal transduction, epithelial biology, and cancer research.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. LI-cadherin may have a role in the morphological organization of liver and intestine. Involved in intestinal peptide transport.

Gene References into Functions

CDH17 has a role in altering MMP-2 expression via canonical NF-kappaB signalling in human gastric cancer PMID:29783070
Data show that alteration in beta-catenin expression, a core component of the CDH17/beta-catenin axis, in tumors affects serine peptidase inhibitor Kazal type 1 (SPINK1) serum levels in hepatocellular carcinoma (HCC) patients. PMID:28631187
However, CDH17 expression was significantly elevated in patients with stage II and III gastric cancers compared to that in healthy controls (p= 0.023 and p= 0.037, respectively). PMID:28453457
CDH17 and CLDN18 are useful target molecules. Their coupling can aid in the comprehensive detection and localization of gastric cancer metastases in vivo to overcome challenges associated with intratumoral heterogeneity. PMID:27580354
CDH17 is a sensitive marker for midgut WDNETs, and the CDH17+/CDX2-/TTF1- phenotype was found to be sensitive (92%) and specific (91%) for hindgut well-differentiated neuroendocrine tumours (WDNETs). PMID:25388236
Using a lentiviral system as a delivery mediator of RNA interference, we found that inhibition of CDH17 can lead to reduce proliferation and increase apoptosis of gastric cancer cell line MKN28 in vitro and significantly diminish their tumorigenicity in vivo. Our results of the present study suggest that CDH17 may be a promising candidate for the therapeutic targeting of gastric cancer. PMID:27909714
In stomach adenocarcinomas, CDH17 positively stained 64.0% (112 of 175) of tissues, compared to CK20 and CDX2, where staining was observed in only 24.6% (43 of 175) and 46.9% (82 of 175), respectively. PMID:28029907
These data indicate that knockdown of LIcadherin facilitates the invasion of cancer cells by degrading extracellular matrix components via activation of MMP2 and 9, and increases cancer cell adhesion and migration via altered expression of galectin3. PMID:27035870
Fascin-1 expression, cadherin-17 expression, tumor size, and differentiation were independent risk factors for GC. PMID:26743780
Mutations in CDH17 gene is associated with idiopathic hypereosinophilic syndrome. PMID:26497854
Review/Meta-analysis: data reflect the role of CDH17 in tumor proliferation and metastasis among gastric cancer patients. PMID:25834338
CDH17 is a sensitive (81%) and highly specific (100%) marker for metanephric adenoma. PMID:25768256
RGD motif present in cadherin 17 induces integrin activation and tumor growth PMID:25336636
Data suggest that combined tumor expression of CDH17 (cadherin-17) and SATB2 (special AT-rich sequence binding protein 2) may be used as diagnostic biomarkers in subjects with medullary carcinoma of the large intestine (colon; cecum). PMID:24437456
Data reveal a new function for CDH17, which is to regulate alpha2beta1 integrin signaling in cell adhesion and proliferation in colon cancer cells for liver metastasis. PMID:23604127
The SNPs of the CDH17 gene c.2216 A>C might be clinically important in the prognosis of colorectal carcinoma. PMID:23326130
This study demonstrates that the secreted form of cadherin-17 (ectodomain) is truncated at the C-terminus. PMID:23557862
results identify CDH17 as a biomarker of gastric carcinoma and attractive therapeutic target for this aggressive malignancy. PMID:23554857
Cadherin-17 induces tumorigenesis and lymphatic metastasis in gastric cancer through activation of NFkappaB signaling pathway. PMID:23298905
LI-cadherin is a sensitive marker of intestinal metaplasia and can be helpful for early histologic diagnosis of Barrett's esophagus (BE); it is not, however, significantly different between BE with and without intestinal epithelial neoplasia. PMID:23053896
Up-regulation of cadherin 17 is associated with epithelial ovarian cancer progression. PMID:22810971
Report less aggressive behavior of gastric tumors after CDH17 gene knockdown. PMID:22791949
CDH17 was positively associated with larger tumor size, deeper invasion, diffuse/mixed histotype, LVI, and LNMM, predicting a poor prognosis in pN0 gastric cancer. PMID:22009269
LI cadherin is associated with an intestinal phenotype and an 'intestinal pathway' of carcinogenesis in intraductal papillary mucinous neoplasm. PMID:22286087
we proposed that CDH17 may be an oncogene up-regulating invasive features of gastric cancer cells PMID:20393816
CDH17 expression may be well preserved during the metastatic process and therefore be a useful marker for identifying colorectal adenocarcinomas in a metastatic setting with an unknown primary site PMID:21323956
Targeting CDH17 in HCC can inhibit tumor growth and inactivate Wnt signaling pathway in concomitance with activation of tumor suppressor genes.[review] PMID:20580775
CDX2 and LI-cadherin are sensitive markers of intestinal metaplasia with or without dysplasia in the upper gastrointestinal tract. PMID:20444732
identified the minimal promoter region of CDH17 that is regulated by HNF1alpha and CDX2 transcriptional factors; Suppression of HNF1alpha and CDX2 expression by siRNA down-regulated expressions of CDH17 and cyclin D1 and the viability of HCC cells PMID:20568120
Li-cadherin participates in the multiple steps of invasion and metastasis in a colorectal cancer cell line. PMID:20204409
CDH17 maybe a positive regulator for proliferative, adhesive, and invasive behaviors of gastric cancer. PMID:20500517
Expression of CDH17 and MUC13 was up-regulated in gastric cancer tissues. CDH17 is a promising prognostic marker for early stage gastric cancer. PMID:20398667
Loss of LI-cadherin results in up-regulation of MTF-1 and PlGF, thereby regulating angiogenesis in intrahepatic cholangiocarcinoma PMID:19956853
High xpression of liver-intestine cadherin and its possible interaction with galectin-3 is associated with ductal adenocarcinoma of the pancreas PMID:12824888
tumor staging and LI-cadherin expression were found to be independent factors associated with lymph node metastasis. PMID:15178443
LI-cadherin may have a role in lymph node metastasis and progression of human colorectal carcinoma PMID:15279905
Aberrant alternative splicing of LI-cadherin is associated with hepatocellular carcinoma PMID:15701831
The functional T-G haplotype of CDH17 (651 C>T and IVS6+35A>G) is a genetic susceptibility factor for the development of Hepatocellular carcinoma (HCC) in a Chinese population. PMID:16951245
Reduced expression of liver intestine-cadherin had a significant correlation with tumoral dedifferentiation and short overall survival in colorectal cancer. PMID:17828401
combined detection of CDH17/CDX2 co-expression may benefit us in predicting the prognosis of gastric carcinoma. PMID:18353622
Cadherin-17 is a useful immunohistochemical marker for diagnosis of adenocarcinomas of the digestive system. PMID:18552820
CDH17 is a novel oncogene in hepatocellular carcinoma. CDH17 is a biomarker and attractive therapeutic target for this aggressive malignancy. PMID:19676131